Tyrosine Kinase Inhibitors Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Tyrosine Kinase Inhibitors Market is segmented by Type (BCR-ABL Tyrosine Kinase Inhibitor​, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors​, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, BRAF Kinase Inhibitors​, ROS1 Inhibitors​, and Other Types​), Application (Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

tyrosine kinase inhibitors market share
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 10.07 %
tyrosine kinase inhibitors market major players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Tyrosine Kinase Inhibitors Market was valued at USD 44,059.89 million in 2021, and it is expected to witness a CAGR of 10.07% over the forecast period.

The COVID-19 pandemic affected health care systems globally and resulted in the interruption of usual care in many health care facilities, exposing vulnerable patients with cancer to significant risks. For instance, a study titled ‘Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study’ in 2020 reported that a total of 356 centers from 54 countries across 6 continents participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer a year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%).​

A tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to a protein in a cell. A tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases. Due to the increasing prevalence of cancer incidence globally, the demand for novel therapies for treatment has increased. Theoretically, TKI, which is a small molecule, has many advantages over traditional therapies, including ease of oral administration and the ability to target multiple cellular survival pathways. As a result, many types of research are done to find cancer treatment theories that involve TKI. Many drugs involving this pathway are under development. These factors are expected to help the growth of the market.

However, high development cost leads to the higher market price of the drug post-approval. Hence, the cost of the drug has been restraining the market growth up to a certain extent.

Scope of the Report

As per the scope of the report, a tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades. The Tyrosine Kinase Inhibitors Market is segmented by Type (BCR-ABL Tyrosine Kinase Inhibitor​, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors​, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, BRAF Kinase Inhibitors​, ROS1 Inhibitors​, and Other Types​), Application (Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Type
BCR-ABL Tyrosine Kinase Inhibitor
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
Other Types
By Application
Chronic Myeloid Leukemia (CML)
Lung Cancer
Breast Cancer
Renal Cell Cancer
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Treatment for Chronic Myeloid Leukaemia Expected to Dominate the Market

Chronic Myeloid Leukemia (CML) is a cancer of the white blood cells that is characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. The incidence of CML has increased over the past few decades as per research by Taisen Hao et al., published in Nature Research Journal 2019. As per the reports, CML cases increased from 4,300 cases in 1998 to 8,430 in 2018, up by 96% in the United States.

CML is primarily treated with targeted drugs called tyrosine-kinase inhibitors (TKIs), which have dramatically improved long-term survival rates since the early 2000s. These drugs are said to have revolutionized the treatment of this disease by allowing most patients to have a good quality of life compared to the former chemotherapy drugs.

Hence, with the growing incidence of CML, the market for tyrosine kinase inhibitors therapies is also expected to increase.

tyrosine kinase inhibitors market forecast

North America Expected to Dominate the Market

The North American countries, including the United States and Canada, have a developed and well-structured health care system. These systems also encourage research and development, especially on cancer. Many companies in these countries have been involved in cancer research. Hence, these policies have encouraged other global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players.

Moreover, the prevalence of cancer is also high in these countries. The prevalence of cancer in the United States is one of the highest globally. TKIs are used to treat cancer; therefore, the growing prevalence of cancer will positively impact market growth. According to the American Cancer Society Inc., in 2021, an estimated 1.9 million new cancer cases and 608,570 cancer deaths were expected in the United States, thus driving the studied market during the forecast period. This high prevalence of cancer has increased the economic burden of cancer in this region.

Product innovation with the tyrosine kinase inhibitors for treating multiple conditions is expected to drive market growth. For instance, in July 2021, Ocular Therapeutix Inc. dosed the first patient in the United States Phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) to treat wet age-related macular degeneration (wet AMD). Thus, the ongoing clinical trial process in the concerned market will boost the studied market.​ Hence, as high demand is met by the presence of global players in the region, the market is further expected to increase.

tyrosine kinase inhibitors market trends

Competitive Landscape

The global key players are manufacturing the majority of the tyrosine kinase inhibitors therapies. Market leaders with more funds for research and a better distribution system have established their position. Moreover, Asia-Pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market grow at a significant rate. Some of the market players include Bayer, Boehringer Ingelheim International, F. Hoffmann-La Roche Ltd, AstraZeneca PLC, and Novartis.

Recent Developments

  • In March 2021, Pfizer Inc. received US Food and Drug Administration approval for supplemental New Drug Application (sNDA) for LORBRENA (lorlatinib), a TKI, expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). LORBRENA is indicated for adults with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved test.
  • In February 2021, Novartis received the Breakthrough Therapy designation (BTD) grant by the United States Food and Drug Administration (FDA) for asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Cancer

      2. 4.2.2 Growing Research Activities and Investment in Tyrosine Kinase Inhibitors

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Therapy

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 5.1 By Type

      1. 5.1.1 BCR-ABL Tyrosine Kinase Inhibitor

      2. 5.1.2 Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors

      3. 5.1.3 Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors

      4. 5.1.4 Other Types

    2. 5.2 By Application

      1. 5.2.1 Chronic Myeloid Leukemia (CML)

      2. 5.2.2 Lung Cancer

      3. 5.2.3 Breast Cancer

      4. 5.2.4 Renal Cell Cancer

      5. 5.2.5 Other Applications

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca PLC

      2. 6.1.2 Bayer AG

      3. 6.1.3 Boehringer Ingelheim International

      4. 6.1.4 Bristol-Myers Squibb Company

      5. 6.1.5 Eisai Co. Ltd

      6. 6.1.6 F. Hoffmann-La Roche Ltd

      7. 6.1.7 Johnson and Johnson

      8. 6.1.8 Novartis International AG

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Eli Lilly and Company ​

      11. 6.1.11 Hansoh Pharma ​

      12. 6.1.12 Spectrum Pharmaceuticals ​

      13. 6.1.13 Takeda Pharmaceutical ​

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Tyrosine Kinase Inhibitors Market market is studied from 2019 - 2027.

The Tyrosine Kinase Inhibitors Market is growing at a CAGR of 10.07% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Bayer, Boehringer Ingelheim International, F. Hoffmann-La Roche, AstraZeneca plc, Novartis International AG are the major companies operating in Tyrosine Kinase Inhibitors Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!